The Effect of Whole Milk to Improve Muscle Health in Older Women

NCT ID: NCT04981652

Last Updated: 2022-04-06

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-06-01

Study Completion Date

2020-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Muscle and strength begin to noticeably decline around 50 years of age, increasing an individual's risk for disease and disability. Although changes in muscle mass ultimately depend on the balance of muscle protein synthesis (MPS) and breakdown (MPB) of muscle proteins, the latter remains relatively constant with aging. Accordingly, interventions that increase rates of MPS may combat long-term decrements in skeletal muscle mass and function. Previous research has established that an optimal diet to maintain muscle mass in elderly individuals requires relatively large amounts of high-quality protein to be consumed at each meal of the day. While this is a seemingly simple strategy, there are some barriers to increasing protein feeding in elderly individuals, particularly the cost of high-quality protein and, sometimes, difficulty with chewing/swallowing. Moreover, older adults often do not wish to consume large portions of protein in one meal.

Milk is a readily accessible, affordable and nutritious source of nutrient-dense high-quality protein. Consuming milk with each meal is an easy strategy to promote the maintenance of skeletal muscle mass with aging. There is also evidence suggesting that a higher fat content of milk can have a beneficial role in stimulating the MPS response to feeding, but there are insufficient data to recommend this strategy to elderly individuals.

The primary aim is to measure the rates of MPS in response to controlled diets providing whole milk, fat-free milk, or a control supplement (almond beverage - often marketed as an 'alternative' to milk) with each meal. All diets will provide equal amounts of energy, but the dairy interventions will provide more protein, reflecting the amount of protein provided by each beverage. The investigators hypothesize that rates of MPS will be highest in the whole milk group but that fat-free milk will still elicit a greater MPS than almond beverage. The investigators will conduct the comparison of beverages under habitual physical activity levels and under a brief period of increased physical activity (i.e., increased daily steps). Thus, the investigators will be able to determine whether MPS responses to the experimental beverages are increased in combination with physical activity. The results will provide evidence regarding the effectiveness of daily milk ingestion for the maintenance of muscle in the elderly, increasing the marketability of milk, and potentially whole milk.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dairy Products Muscle Protein Synthesis Aging Physical Activity

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Participants randomly assigned to one of three intervention groups (whole milk, skim milk or almond beverage)
Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

SINGLE

Participants
Participant was blinded by formulating intervention beverages to have a similar taste profile with noncaloric, non-nutritional flavouring additives

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Whole Milk

Participants randomly assigned to the whole milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two whole milk experimental beverages (250 mL each serving, 3% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to \~150% of their habitual levels.

Group Type EXPERIMENTAL

Whole Milk

Intervention Type DIETARY_SUPPLEMENT

Participants will consume twice daily whole milk beverages in addition to a standardized diet.

Skim Milk

Participants randomly assigned to the skim milk condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two skim milk experimental beverages (250 mL each serving, 0% milk fat) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to \~150% of their habitual levels.

Group Type EXPERIMENTAL

Skim Milk

Intervention Type DIETARY_SUPPLEMENT

Participants will consume twice daily skim milk beverages in addition to a standardized diet.

Almond Beverage

Participants randomly assigned to the almond beverage condition will undergo three sequential study phases, each lasting three days in length. During phase 1, these participants will participate in habitual physical activity and consume a standardized diet, delivering 0.8 g/kg/body mass per day of protein. During the second phase, participants in this group will continue to perform habitual activity, but will have two almond experimental beverages (250 mL each serving) added to their standardized diet each day for the three day period. Finally, during the last three days of the study, participants will continue to consume the their intervention diet, but their physical activity levels (monitored via daily step count) will be increased to \~150% of their habitual levels.

Group Type EXPERIMENTAL

Almond Beverage

Intervention Type DIETARY_SUPPLEMENT

Participants will consume twice daily almond beverages in addition to a standardized diet.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Whole Milk

Participants will consume twice daily whole milk beverages in addition to a standardized diet.

Intervention Type DIETARY_SUPPLEMENT

Skim Milk

Participants will consume twice daily skim milk beverages in addition to a standardized diet.

Intervention Type DIETARY_SUPPLEMENT

Almond Beverage

Participants will consume twice daily almond beverages in addition to a standardized diet.

Intervention Type DIETARY_SUPPLEMENT

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Be between the ages of 60-75 years (inclusive)
* Be at least 5 years post-menopausal
* Have a body mass index (BMI) between 20-35 kg/m2
* Be able to maintain a habitual diet, physical activity patterns, and body mass throughout the trial
* Be in general good health
* Understand the study procedures and sign this form providing informed consent to participate in the study.
* Understand the study procedures and sign the form providing informed consent to participate in the study.

Exclusion Criteria

* Use of tobacco or related products
* Use assistive walking devices (e.g., cane or walker)
* A history of neuromuscular problems or muscle and/or bone wasting diseases
* Any acute or chronic illness; cardiac, pulmonary, liver, or kidney abnormalities; insulin- or non-insulin-dependent diabetes or other metabolic disorders (all ascertained through medical questionnaires)
* Use of medications known to affect protein metabolism (i.e. corticosteroids, nonsteroidal anti-inflammatory drugs (prescription use or daily use of over the counter medication), or prescription strength acne medications)
* Use of anticoagulant medication
* History of statin myalgia
* Allergy to lactose or almonds
* Consuming a vegan diet
Minimum Eligible Age

60 Years

Maximum Eligible Age

75 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

McMaster University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Stuart Phillips

Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Exercise Metabolism Research Laboratory, McMaster Univeristy

Hamilton, Ontario, Canada

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Canada

References

Explore related publications, articles, or registry entries linked to this study.

Stokes T, Mei Y, Seo F, McKendry J, McGlory C, Phillips SM. Dairy and Dairy Alternative Supplementation Increase Integrated Myofibrillar Protein Synthesis Rates, and Are Further Increased when Combined with Walking in Healthy Older Women. J Nutr. 2022 Jan 11;152(1):68-77. doi: 10.1093/jn/nxab358.

Reference Type RESULT
PMID: 34610129 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

HIREB 4832

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.